Azitra Inc. is a clinical-stage biopharmaceutical company focused on precision dermatology. The company develops topical live biotherapeutic products and engineered protein-based therapeutics designed to address skin diseases by working with the skin microbiome. Its platform combines synthetic biology, microbial engineering, and protein design to create treatments for dermatologic conditions, including rare and hard-to-treat disorders. Azitra Inc. also uses a proprietary microbial library and data-driven screening tools to identify bacterial strains with therapeutic potential. The company’s current product portfolio includes investigational candidates aimed at dermatology and skin-barrier disorders, positioning Azitra Inc. within the specialized market for microbiome-based skin treatments and targeted dermatologic therapeutics.
Website21 Business Park Drive
Branford, CT, 06405
United States
Detailed price information for Azitra Inc (AZTR-A) from The Globe and Mail including charting and trades.
Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced that it has received written notification from NYSE American LLC ("NYSE American") confirming that the Company has regained compliance with all of the NYSE American continued listing standards set forth in Part 10 of the NYSE American Company Guide.
Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today reported financial results for the quarter ended June 30, 2026, and provided a business update.
Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced promising results from two separate ex vivo human skin tissue studies. The studies evaluated the distribution and anti-wrinkle activity of Azitra's filaggrin domain containing supernatant in two separate experimental studies.
Investors talking about AZTR also mention
What share of all stock conversation is about AZTR?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% 0 | 0% 0 | 0% 0 |
Of the messages about AZTR that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | — | 91.06% +6.5 | ||
| Bearish | — | — | — | 8.94% -6.5 |
Of the messages about AZTR that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | — | 100% | 21.97% | ||
| Controversies | — | — | 0% | 0.09% | ||
| Technical Analysis | — | — | 0% | 33.35% | ||
| Analysts | — | — | 0% | 21.54% | ||
| Earnings | — | — | 0% | 0% | ||
| Macro | — | — | 0% | 23.05% |
Of the messages about AZTR, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | — | — | 100% | 31.72% | ||
| Newcomers | — | — | 0% | 68.28% |